Positive commentary but then PT lowered from today's Globe * Ahead of its Nov. 7 earnings release, Ventum Capital Markets’ Rob Goff lowered his Well Health Technologies Corp. (
) target to $7 from $8 with a “buy” rating. The average is $7.61.
“We view WELL as a top performer in healthcare technology in Canada. Over the next 3 to 12 months, we expect the Company to extend its track record of delivering double-digit organic growth in alignment with WELL’s rule of 30 (combined organic revenue plus the EBITDA margin exceeding 30 per cent) and to build shareholder value,” he said. “We look for positive catalysts around portfolio monetizations, ongoing tuck-in acquisitions along with absorptions layered onto double-digit organic growth.”